Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darel Benvenuti

Cardiovascular Disease Newport Beach, CA Medical Doctor

NPI 1912915364 CMS profile 313429

355 Placentia Ave, Suite 100, Newport Beach, CA 92663

Open in the dashboard

General payments

$9,380

444 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darel Benvenuti of Newport Beach, CA is reported in the CMS Open Payments database as having received $9,380 across 444 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,785 90
2024 General $2,153 109
2023 General $2,108 88
2022 General $1,391 59
2021 General $942 49
2020 General $293 14
2019 General $708 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darel Benvenuti
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Darel Benvenuti were reported at $1,785. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Darel Benvenuti Cardiovascular Disease median Middle half National median
2019 $708 $450 $127–$1,392 $163
2020 $293 $242 $77–$751 $114
2021 $942 $335 $101–$1,037 $132
2022 $1,391 $395 $121–$1,211 $149
2023 $2,108 $443 $136–$1,283 $160
2024 $2,153 $450 $136–$1,323 $164
2025 $1,785 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $975 48 payments
  2. Pfizer Inc. $820 47 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $720 57 payments
  4. Amgen Inc. $654 32 payments
  5. E.R. Squibb & Sons, L.L.C. $600 33 payments
  6. Abbott Laboratories $516 17 payments
  7. Janssen Pharmaceuticals, Inc $425 24 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $409 23 payments
  9. CVRx, Inc. $373 8 payments
  10. Boston Scientific Corporation $365 14 payments
  11. Other $3,520 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,180 443 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $720 57 payments
  2. LEQVIO $639 27 payments
  3. Repatha $540 26 payments
  4. VYNDAQEL $525 31 payments
  5. ELIQUIS $437 29 payments
  6. XARELTO $425 24 payments
  7. CAMZYOS $414 23 payments
  8. Barostim Neo System $373 8 payments
  9. ENTRESTO $281 12 payments
  10. VERQUVO $261 14 payments
  11. Other $5,868 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

9,695

Median for Cardiology: 2,533

Drug cost

$1,955,679

Median for Cardiology: $485,213

Branded share of claims

26.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 493 $618,511
Vyndamax Tafamidis Brand 15 $355,200
Xarelto Rivaroxaban Brand 270 $283,138
Repatha Sureclick Evolocumab Brand 143 $133,801
Entresto Sacubitril/Valsartan Brand 86 $104,800
Praluent Pen Alirocumab Brand 88 $63,325
Farxiga Dapagliflozin Propanediol Brand 47 $52,708
Jardiance Empagliflozin Brand 31 $37,697
Brilinta Ticagrelor Brand 28 $28,149
Ozempic Semaglutide Brand 28 $27,890

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$431,280

Of which drugs: $2,520

Medicare patients

1,214

Average age 78

Services billed

6,427

600 women, 614 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 41%
Atrial fibrillation 36%
Diabetes 29%
Chronic kidney disease 29%
Heart failure 23%
Cancer 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 104 416 $2,520

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $226
$226 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $178
$178 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $136
$136 31 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $133
$133 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $108
$108 270 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

444 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record